The effect of Dabigatran on select specialty coagulation assays

Dorothy M. Adcock, Robert Gosselin, Steve Kitchen, Denis M Dwyre

Research output: Contribution to journalArticlepeer-review

69 Scopus citations


Dabigatran etexilate is a new oral anticoagulant that functions as a direct thrombin inhibitor. An inhibitor of thrombin has the potential to interfere with essentially all clot-based coagulation assays and select chromogenic assays, whereas the drug would not be expected to interfere in antigen-based assays. The purpose of this study was to evaluate the effect of dabigatran on various specialized coagulation assays using normal plasma specimens with varying concentrations of dabigatran (the active form of dabigatran etexilate). We have demonstrated that samples containing therapeutic levels of dabigatran may lead to underestimation of intrinsic factor activities with abnormal activated partial thromboplastin time (aPTT) mixing study results and a false-positive factor VIII Bethesda titer; overestimation of protein C and protein S activity and activated protein C resistance ratio when determined using aPTT-based methods; and overestimation of results based on chromogenic anti-IIa assays but no effect on antigen assays and select chromogenic assays.

Original languageEnglish (US)
Pages (from-to)102-109
Number of pages8
JournalAmerican Journal of Clinical Pathology
Issue number1
StatePublished - Jan 2013


  • Activated protein C resistance
  • Antithrombin
  • Bethesda assay
  • Dabigatran
  • Direct thrombin inhibitor
  • Factor assays
  • Protein C
  • Protein S
  • Special coagulation assays

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'The effect of Dabigatran on select specialty coagulation assays'. Together they form a unique fingerprint.

Cite this